Across 207 European Cardiology Phase III CTIS trials authorized in 2024–2026, 82/207 trials (39.6%) listed explicit CRO support. IQVIA was the most active CRO with 31 supported trials, followed by ICON Clinical Research with 24 and Parexel/Perceptive with 19. CRO need was strongest when CTIS/EU submission footprints reached 11+ countries (18/21; 85.7%), 51+ sites (13/18; 72.2%), or 3,000+ planned participants (18/27; 66.7%).
Among the 82 trials with explicit CRO support, IQVIA appeared in 31 trials (37.8%), ICON Clinical Research in 24 (29.3%), and Parexel/Perceptive in 19 (23.2%). The ranking counts distinct trial appearances, not contract value.
The CRO market is broad but not evenly distributed: three large global providers account for the highest visible trial presence, while laboratory, eClinical, IRT, and specialty providers appear frequently as function-specific outsourcing partners.
CRO support increased sharply with operational footprint. Trials spanning 11+ countries used CROs in 18/21 cases (85.7%); trials with 51+ European sites used CROs in 13/18 cases (72.2%); and trials planning 3,000+ participants used CROs in 18/27 cases (66.7%).
The strongest capacity trigger is not simply sample size; it is multi-country CTIS/EU execution. Once a trial moves beyond 6 countries or 21 sites, CRO support becomes the dominant operating model.
CRO use was highest in Atherosclerotic cardiovascular disease (17/22; 77.3%), Cardiac amyloidosis (9/12; 75.0%), Pulmonary arterial hypertension (6/8; 75.0%), and Lipid disorders/hypercholesterolemia (7/10; 70.0%). Heart failure had the largest broad disease workload among major indications, with 15/28 trials (53.6%) using CRO support.
CRO demand concentrates where cardiology trials combine large event-driven outcomes, specialist sites, imaging or biomarker workflows, and multi-country regulatory execution. ASCVD and heart failure produce the biggest absolute workload; amyloidosis, PAH, and lipid disorders show the highest proportional CRO reliance.
The largest CRO-supported CTIS country footprints were Spain (52 trial-country records), Italy (43), Germany (42), France (39), Poland (38), and Czechia (35). Among countries with at least 10 trial-country records, CRO-use rates were highest in Romania (11/12; 91.7%), Portugal (19/21; 90.5%), Greece (21/24; 87.5%), Hungary (23/27; 85.2%), and Czechia (35/42; 83.3%).
Large Western European markets drive the absolute volume of CRO-supported activity, but CRO reliance is proportionally highest in several Central, Eastern, and Southern European CTIS country operations where local submission, contracts, site activation, and language workflows often require execution depth.
Third-party outsourcing appeared in 126/207 trials (60.9%). The most common outsourced functions were Clinical operations/CRO management (69/207; 33.3%), Central laboratory/bioanalysis (61/207; 29.5%), Randomisation/IRT/supply logistics (48/207; 23.2%), eCOA/ePRO or digital patient data (40/207; 19.3%), and Imaging/ECG/cardiac diagnostics (29/207; 14.0%).
Cardiology outsourcing is functionally specialized. Even when a record does not list a single full-service CRO, sponsors frequently outsource the operational spine: site execution, laboratories, randomisation/IRT, eCOA/ePRO, imaging/ECG review, endpoint adjudication, and CTIS/regulatory support.
The same dataset answers several adjacent operational questions numerically: CRO use rose from 34/108 trials in 2024 (31.5%) to 19/34 in 2026 (55.9%); adaptive designs used CROs in 8/9 trials (88.9%); digital recruitment trials used CROs in 29/42 cases (69.0%); and orphan-drug cardiology trials used CROs in 13/17 cases (76.5%).
The strongest additional signal is that CRO support is associated with complex execution rather than with phase alone: adaptive design, orphan-drug status, digital recruitment, and multi-country CTIS Part II workflows all show above-average CRO reliance.
CRO means contract research organisation. CTIS means Clinical Trials Information System, the EU portal used for clinical-trial applications and country-level Part II submissions. IRT means interactive response technology for randomisation and drug-supply management. eCOA/ePRO means electronic clinical outcome assessment/electronic patient-reported outcome. DMC means data monitoring committee.